JAK-IN-13
JAK-IN-13 is a pan-JAK inhibitor. JAK-IN-13 inhibits JAK1, JAK2, JAK3, and Tyk2, with human IC50 values of 5.5 nM, 1.5 nM, 3.5 nM, and 130 nM, respectively. JAK-IN-13 inhibits neutrophilia and reduces IL-6 levels in an acute rat model of airway inflammation. JAK-IN-13 can be used for research on airway inflammation.
For research use only. We do not sell to patients.
- CAS No.: 1414805-62-1
- Formula: C18H19N7O2
- Molecular Weight:365.39
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
JAK1 5.5 nM (IC50) |
JAK2 1.5 nM (IC50) |
JAK3 3.5 nM (IC50) |
IL-6 |
Tyk2 130 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Ramos | IC50 |
41 nM
|
Inhibition of IL-4-induced STAT-6 phosphorylation in human Ramos cells.
Inhibition of IL-4-induced STAT-6 phosphorylation in human Ramos cells.
|
31609613 |
| Monocyte | IC50 |
219 nM
|
Inhibition of GM-CSF-stimulated STAT-5 phosphorylation in human PBMC-derived monocytes.
Inhibition of GM-CSF-stimulated STAT-5 phosphorylation in human PBMC-derived monocytes.
|
31609613 |
| CHO | IC50 |
100 μM
|
Cytotoxicity against Chinese hamster ovary (CHO) cells with IC50 > 100 μM.
Cytotoxicity against Chinese hamster ovary (CHO) cells with IC50 > 100 μM.
|
31609613 |
In Vitro
JAK-IN-13 (Compound 34) inhibits IL-4-induced STAT-6 phosphorylation in human Ramos cells with IC50 = 41 nM[1].
JAK-IN-13 inhibits GM-CSF-stimulated STAT-5 phosphorylation in human monocytes with IC50 = 219 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:rat[1]
-
Dosage:0.01, 0.1, 1, and 3 mg/kg
-
Administration:aerosolized nanosuspension, using phosphate-buffered
saline containing 0.2% Tween 80 and 0.3% methylcellulose as
vehicle -
Result:Significantly reduced IL-6 levels in bronchoalveolar lavage fluid (62% reduction).
Inhibited neutrophilia, with the strongest inhibitory effect observed at a dose of 3 mg/kg (56% inhibition rate).
Chemical Information
-
CAS No. 1414805-62-1
-
Molecular Weight 365.39
-
Formula C18H19N7O2
-
SMILES
N#CC[C@@H]1CC[C@@H](N2C(NC3=CN=C(NC4=CC=CNC4=O)N=C23)=O)CC1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)